349 related articles for article (PubMed ID: 30347396)
1. Hyperprolactinemia/Prolactinomas in the Postmenopausal Period: Challenges in Diagnosis and Management.
Pekić S; Medic Stojanoska M; Popovic V
Neuroendocrinology; 2019; 109(1):28-33. PubMed ID: 30347396
[TBL] [Abstract][Full Text] [Related]
2. [Hyperprolactinemia in the postmenopause: versions and contraversions].
Leshchenko OY
Ter Arkh; 2021 Oct; 93(10):1234-1239. PubMed ID: 36286827
[TBL] [Abstract][Full Text] [Related]
3. Hyperprolactinemia after menopause: Diagnosis and management.
Auriemma RS; Pirchio R; Pivonello R; Colao A
Maturitas; 2021 Sep; 151():36-40. PubMed ID: 34446277
[TBL] [Abstract][Full Text] [Related]
4. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
5. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
[TBL] [Abstract][Full Text] [Related]
6. Management of prolactinomas: a survey of physicians from the Middle East and North Africa.
Beshyah SA; Sherif IH; Chentli F; Hamrahian A; Khalil AB; Raef H; El-Fikki M; Jambart S
Pituitary; 2017 Apr; 20(2):231-240. PubMed ID: 27783196
[TBL] [Abstract][Full Text] [Related]
7. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
9. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
[TBL] [Abstract][Full Text] [Related]
10. Prolactinoma in postmenopausal women: a systematic review.
Carneiro MS; de Mira TAA; Yela DA; Benetti-Pinto CL
Menopause; 2024 Feb; 31(2):160-167. PubMed ID: 38194617
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas and menopause: any changes in management?
Greenman Y
Pituitary; 2020 Feb; 23(1):58-64. PubMed ID: 31686376
[TBL] [Abstract][Full Text] [Related]
12. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women.
Colao A; Di Sarno A; Guerra E; De Leo M; Mentone A; Lombardi G
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):200-10. PubMed ID: 16932285
[TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
14. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
15. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
[TBL] [Abstract][Full Text] [Related]
16. Prolactinomas: evolution after menopause.
Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
[TBL] [Abstract][Full Text] [Related]
17. Approach to the Patient With Prolactinoma.
Auriemma RS; Pirchio R; Pivonello C; Garifalos F; Colao A; Pivonello R
J Clin Endocrinol Metab; 2023 Aug; 108(9):2400-2423. PubMed ID: 36974474
[TBL] [Abstract][Full Text] [Related]
18. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
Sosa-Eroza E; Espinosa-Cárdenas E
Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas diagnosed in the postmenopausal period: Clinical phenotype and outcomes.
Santharam S; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Webster R; Karavitaki N
Clin Endocrinol (Oxf); 2017 Nov; 87(5):508-514. PubMed ID: 28626987
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
Ono M; Miki N; Kawamata T; Makino R; Amano K; Seki T; Kubo O; Hori T; Takano K
J Clin Endocrinol Metab; 2008 Dec; 93(12):4721-7. PubMed ID: 18812485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]